Paper7941328
Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
Spear GT and 4 others. Virology, 1994. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization. Papers, record 7941328. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7941328
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Antibodies to the HIV-1 V3 loop in serum from infected persons contribute a major proportion of immune effector functions including complement activation, antibody binding, and neutralization.
- PubMed
- Publication types
- Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Acquired Immunodeficiency Syndrome | Major topic |
| Complement Activation | Major topic |
| HIV Antibodies | Major topic |
| HIV-1 | Major topic |
| Amino Acid Sequence | |
| Complement C3 | |
| Humans | |
| Molecular Sequence Data | |
| Neutralization Tests |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| AI29661 | NIAID NIH HHS | United States | R01AI029661 | PubMed and NIH | NIH RePORTER |
| AI31812 | NIAID NIH HHS | United States | R01AI031812 | PubMed and NIH | NIH RePORTER |
| AI32424 | NIAID NIH HHS | United States | R01AI032424 | PubMed and NIH | NIH RePORTER |
| R29AI031812 | NIH | NIH RePORTER |
Cited by18
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31833228 | Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells. | EMBO Rep | 2020 | https://conductscience.org/library/papers/31833228 | PubMed |
| 29237828 | Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates. | J Virol | 2018 | https://conductscience.org/library/papers/29237828 | PubMed |
| 27657055 | Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/27657055 | PubMed |
| 26842476 | Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. | J Virol | 2016 | https://conductscience.org/library/papers/26842476 | PubMed |
| 26109728 | Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL. | J Virol | 2015 | https://conductscience.org/library/papers/26109728 | PubMed |
| 25122783 | Visualization of retroviral envelope spikes in complex with the V3 loop antibody 447-52D on intact viruses by cryo-electron tomography. | J Virol | 2014 | https://conductscience.org/library/papers/25122783 | PubMed |
| 24314667 | Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking. | Virology | 2014 | https://conductscience.org/library/papers/24314667 | PubMed |
| 22012269 | Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. | Arch Virol | 2012 | https://conductscience.org/library/papers/22012269 | PubMed |
| 15039757 | Identifying epitopes of HIV-1 that induce protective antibodies. | Nat Rev Immunol | 2004 | https://conductscience.org/library/papers/15039757 | PubMed |
| 12719582 | Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. | J Virol | 2003 | https://conductscience.org/library/papers/12719582 | PubMed |
| 12186887 | Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. | J Virol | 2002 | https://conductscience.org/library/papers/12186887 | PubMed |
| 11752155 | A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. | J Virol | 2002 | https://conductscience.org/library/papers/11752155 | PubMed |
| 10364275 | Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. | J Virol | 1999 | https://conductscience.org/library/papers/10364275 | PubMed |
| 10233749 | B lymphocytes in lymph nodes and peripheral blood are important for binding immune complexes containing HIV-1. | Immunology | 1999 | https://conductscience.org/library/papers/10233749 | PubMed |
| 9811721 | Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. | J Virol | 1998 | https://conductscience.org/library/papers/9811721 | PubMed |
| 9765439 | Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants. | J Virol | 1998 | https://conductscience.org/library/papers/9765439 | PubMed |
| 9371578 | The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain. | J Virol | 1997 | https://conductscience.org/library/papers/9371578 | PubMed |
| 7666524 | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. | J Virol | 1995 | https://conductscience.org/library/papers/7666524 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| C3 | 718 | PubTator's text mining | https://conductscience.org/library/genes/718 | NCBI Gene |
| ENPEP | 2028 | PubTator's text mining | https://conductscience.org/library/genes/2028 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7941328
GET https://conductscience.org/api/papers/v1/7941328/authors